The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Non‐nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability
Open accessAbstract
Introduction: Human immunodeficiency virus (HIV) type‐1 non‐nucleoside and nucleoside reverse transcriptase inhibitors (NNRTIs) are key drugs of highly active antiretroviral therapy (HAART) in the clinical management of acquired immune deficiency syndrome (AIDS)/HIV infection. Discussion: First‐generation NNRTIs, nevirapine (NVP), delavirdine (DLV) and efavirenz (EFV) are drugs with a low genetic barrier and poor resistance profile, which has led to the development of new generations of NNRTIs. Second‐generation NNRTIs, etravirine (ETR) and rilpivirine (RPV) have been approved by the Food and Drug Administration and European Union, and the next generation of drugs is currently being clinically developed. This review describes recent clinical data, pharmacokinetics, metabolism, pharmacodynamics, safety and tolerability of commercialized NNRTIs, including the effects of sex, race and age differences on pharmacokinetics and safety. Moreover, it summarizes the characteristics of next‐generation NNRTIs: lersivirine, GSK 2248761, RDEA806, BILR 355 BS, calanolide A, MK‐4965, MK‐1439 and MK‐6186. Conclusions: This review presents a wide description of NNRTIs, providing useful information for researchers interested in this field, both in clinical use and in research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,782
Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents
(1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-12_part_2-199806151-00003 · Cited by 5,209
The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals
(1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-113-6-487_2 · Cited by 4,500
Arky, R. A. (1994) · Cited by 2,632
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Thompson Coon, J. (2002) · Focus on Alternative and Complementary Therapies · doi:10.1111/j.2042-7166.2002.tb05480.x · Cited by 1,744
Molecular Properties of WHO Essential Drugs and Provisional Biopharmaceutical Classification
Kasim, N. A., Whitehouse, M., Ramachandran, C., Bermejo, M., Lennernäs, H., Hussain, A. S., Junginger, H. E., Stavchansky, S. A., Midha, K. K., Shah, V. P., et al. (2004) · Molecular Pharmaceutics · doi:10.1021/mp034006h · Cited by 847
Marzolini, C., Telenti, A., Decosterd, L. A., Greub, G., Biollaz, J., & Buclin, T. (2001) · AIDS · doi:10.1097/00002030-200101050-00011 · Cited by 840
Hirsch, M. S., Brun-Vézinet, F., D'Aquila, R. T., Hammer, S. M., Johnson, V. A., Kuritzkes, D. R., Loveday, C., Mellors, J. W., Clotet, B., Conway, B., et al. (2000) · JAMA · doi:10.1001/jama.283.18.2417 · Cited by 766
Reduced Rate of Disease Development After HIV-2 Infection as Compared to HIV-1
Marlink, R., Kanki, P., Thior, I., Travers, K., Eisen, G., Siby, T., Traore, I., Hsieh, C.-C., Dia, M. C., Gueye, E.-H., et al. (1994) · Science · doi:10.1126/science.7915856 · Cited by 633
Ward, B. A., Gorski, J. C., Jones, D. R., Hall, S. D., Flockhart, D. A., & Desta, Z. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.049601 · Cited by 593
Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy
Richman, D. D., Havlir, D., Corbeil, J., Looney, D., Ignacio, C., Spector, S. A., Sullivan, J., Cheeseman, S., Barringer, K., & Pauletti, D. (1994) · Journal of Virology · doi:10.1128/jvi.68.3.1660-1666.1994 · Cited by 576
Hirsch, M. S., Günthard, H. F., Schapiro, J. M., Brun‐Vézinet, F., Clotet, B., Hammer, S. M., Johnson, V. A., Kuritzkes, D. R., Mellors, J. W., Pillay, D., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/589297 · Cited by 573
Gulick, R. M., Ribaudo, H. J., Shikuma, C. M., Lustgarten, S., Squires, K. E., Meyer, W. A., Acosta, E. P., Schackman, B. R., Pilcher, C. D., Murphy, R. L., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031772 · Cited by 522
(2002) · PsycEXTRA Dataset · doi:10.1037/e548362006-001 · Cited by 517
Madruga, J. V., Cahn, P., Grinsztejn, B., Haubrich, R., Lalezari, J., Mills, A., Pialoux, G., Wilkin, T., Peeters, M., Vingerhoets, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61047-2 · Cited by 517
Das, K., Clark, Lewi, P. J., Heeres, J., de Jonge, M. R., Koymans, L. M. H., Vinkers, H. M., Daeyaert, F., Ludovici, D. W., Kukla, M. J., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030558s · Cited by 514
The Physicians' Desk Reference: Problems and Possible Improvements
Cohen, J. S. (1996) · Archives of Internal Medicine · doi:10.1001/archinte.1996.00440120021003 · Cited by 428
Lewis, S. (2004) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200407010-00001 · Cited by 423
de Béthune, M.-P. (2010) · Antiviral Research · doi:10.1016/j.antiviral.2009.09.008 · Cited by 401
Lazzarin, A., Campbell, T., Clotet, B., Johnson, M., Katlama, C., Moll, A., Towner, W., Trottier, B., Peeters, M., Vingerhoets, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61048-4 · Cited by 392
Human immunodeficiency virus type 2
Reeves, J. D., & Doms, R. W. (2002) · Journal of General Virology · doi:10.1099/0022-1317-83-6-1253 · Cited by 369
De Clercq, E. (1998) · Antiviral Research · doi:10.1016/s0166-3542(98)00025-4 · Cited by 358
Janssen, P. A. J., Lewi, P. J., Arnold, E., Daeyaert, F., de Jonge, M., Heeres, J., Koymans, L., Vinkers, M., Guillemont, J., Pasquier, E., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm040840e · Cited by 347
HIV-1 Antiretroviral Resistance: Scientific Principles and Clinical Applications
Tang, M. W., & Shafer, R. W. (2012) · Drugs · doi:10.2165/11633630-000000000-00000 · Cited by 326
Azijn, H., Tirry, I., Vingerhoets, J., de Béthune, M.-P., Kraus, G., Boven, K., Jochmans, D., Van Craenenbroeck, E., Picchio, G., & Rimsky, L. T. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00986-09 · Cited by 293
Erickson, D. A., Mather, G., Trager, W. F., Levy, R. H., & Keirns, J. J. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)14960-4 · Cited by 277
Bacheler, L. T., Anton, E. D., Kudish, P., Baker, D., Bunville, J., Krakowski, K., Bolling, L., Aujay, M., Wang, X. V., Ellis, D., et al. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.9.2475-2484.2000 · Cited by 268
Haubrich, R. H., Riddler, S. A., DiRienzo, A. G., Komarow, L., Powderly, W. G., Klingman, K., Garren, K. W., Butcher, D. L., Rooney, J. F., Haas, D. W., et al. (2009) · AIDS · doi:10.1097/qad.0b013e32832b4377 · Cited by 254
Das, K., Lewi, P. J., Hughes, S. H., & Arnold, E. (2005) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2004.07.001 · Cited by 225
Maggiolo, F., Ravasio, L., Ripamonti, D., Gregis, G., Quinzan, G., Arici, C., Airoldi, M., & Suter, F. (2005) · Clinical Infectious Diseases · doi:10.1086/426595 · Cited by 224
Gender Differences in Adverse Drug Reactions
Tran, C., Knowles, S. R., Liu, B. A., & Shear, N. H. (1998) · The Journal of Clinical Pharmacology · doi:10.1177/009127009803801103 · Cited by 217
Burger, D., Van Der Heiden, I., La Porte, C., Van Der Ende, M., Groeneveld, P., Richter, C., Koopmans, P., Kroon, F., Sprenger, H., Lindemans, J., et al. (2006) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02536.x · Cited by 209
Sex Differences in Nevirapine Rash
Bersoff-Matcha, S. J., Miller, W. C., Aberg, J. A., van der Horst, C., Hamrick, H. J., Powderly, W. G., & Mundy, L. M. (2001) · Clinical Infectious Diseases · doi:10.1086/317536 · Cited by 207
Geographical distribution of HIV-1 group O viruses in Africa
Peeters, M., Gueye, A., Mboup, S., Bibollet-Ruche, F., Ekaza, E., Mulanga, C., Ouedrago, R., Gandji, R., Mpele, P., Dibanga, G., et al. (1997) · AIDS · doi:10.1097/00002030-199704000-00013 · Cited by 183
Cohen, C. J., Molina, J., Cahn, P. E., Clotet, B., Fourie, J., Grinsztejn, B. G. J., Wu, H., Johnson, M. A., Saag, M. S., Supparatpinyo, K., et al. (2012) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31824d006e · Cited by 157
6th IAS Conference on HIV Pathogenesis, Treatment and Prevention
松下, 修. (2011) · HIV感染症とAIDSの治療 · Cited by 153
Efavirenz in the therapy of HIV infection
Rakhmanina, N. Y., & van den Anker, J. N. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250903483207 · Cited by 139
van Heeswijk, R. P. G., Veldkamp, A. I., Mulder, J. W., Meenhorst, P. L., Wit, F. W. N. M., Lange, J. M. A., Danner, S. A., Foudraine, N. A., Kwakkelstein, M. O., Reiss, P., et al. (2000) · AIDS · doi:10.1097/00002030-200005260-00001 · Cited by 130
Inhibition of Human Cytochrome P450 Isoforms by Nonnucleoside Reverse Transcriptase Inhibitors
Moltke, L. L., Greenblatt, D. J., Granda, B. W., Giancarlo, G. M., Duan, S. X., Daily, J. P., Harmatz, J. S., & Shader, R. I. (2001) · The Journal of Clinical Pharmacology · doi:10.1177/00912700122009728 · Cited by 127
Pozniak, A., Morales-Ramirez, J. O., Katabira, E. T., Steyn, D., Lupo, S., Santoscoy, M., Grinsztejn, B. G. J., Ruxrungtham, K., Rimsky, L. T., Vanveggel, S., et al. (2009) · AIDS · doi:10.1097/qad.0b013e32833032ed · Cited by 121
Delavirdine: A Review of its Use in HIV Infection
Scott, L. J., & Perry, C. M. (2000) · Drugs · doi:10.2165/00003495-200060060-00013 · Cited by 115
Borrás‐Blasco, J., Navarro‐Ruiz, A., Borrás, C., & Castera, E. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn292 · Cited by 106
Stöhr, W., Back, D. J., Dunn, D. T., Sabin, C. A., Winston, A., Gilson, R. J. C., Pillay, D., Hill, T., Ainsworth, J., Pozniak, A., et al. (2008) · Antiviral Therapy · doi:10.1177/135965350801300507 · Cited by 104
Creagh-Kirk, T., Ruckle, J., Tolbert, D. T., Giltner, J., Eiznhamer, D. A., Dutta, B., Flavin, M. T., & Xu, Z. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.5.1379-1386.2001 · Cited by 102
Antiretroviral pharmacokinetic profile: A review of sex differences
Ofotokun, I., Chuck, S. K., & Hitti, J. E. (2007) · Gender Medicine · doi:10.1016/s1550-8579(07)80025-8 · Cited by 101
Population pharmacokinetic meta-analysis with efavirenz
Barrett, J. S., Joshi, A., Chai, M., Ludden, T. M., Fiske, W. D., & Pieniaszek, H. J. (2002) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp40507 · Cited by 95
Demeter, L. M., Shafer, R. W., Meehan, P. M., Holden‐Wiltse, J., Fischl, M. A., Freimuth, W. W., Para, M. F., & Reichman, R. C. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.3.794-797.2000 · Cited by 89
Pharmacokinetics and drug–drug interactions of antiretrovirals: An update
Dickinson, L., Khoo, S., & Back, D. J. (2009) · Antiviral Research · doi:10.1016/j.antiviral.2009.07.017 · Cited by 79
Design of Annulated Pyrazoles as Inhibitors of HIV-1 Reverse Transcriptase
Sweeney, Z. K., Harris, S. F., Arora, N., Javanbakht, H., Li, Y., Fretland, J., Davidson, J. P., Billedeau, J. R., Gleason, S. K., Hirschfeld, D. R., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800527x · Cited by 76
Influence of gender on the pharmacokinetics and pharmacodynamics of drugs.
Thürmann, P., & Hompesch, B. C. (1998) · PubMed · Cited by 73
Pauwels, R., Andries, K., Debyser, Z., Kukla, M. J., Schols, D., Breslin, H. J., Woestenborghs, R. J. H., Desmyter, J., Janssen, M. A. C., & Clercq, E. D. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.12.2863 · Cited by 72
Voorman, R. L., Maio, S. M., Hauer, M. J., Sanders, P. E., Payne, N. A., & Ackland, M. J. (1998) · PubMed · Cited by 52
Effects of Different Meal Compositions and Fasted State on the Oral Bioavailability of Etravirine
Schöller‐Gyüre, M., Boffito, M., Pozniak, A., Leemans, R., Kakuda, T. N., Woodfall, B., Vyncke, V., Peeters, M., Vandermeulen, K., & Hoetelmans, R. M. W. (2008) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.28.10.1215 · Cited by 50
The role of nevirapine in the treatment of HIV-1 disease
Fumero, E., & Podzamczer, D. (2001) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2.12.2065 · Cited by 44
Fätkenheuer, G., Staszewski, S., Plettenburg, A., Hackman, F., Layton, G. R., McFadyen, L., Davis, J. D., & Jenkins, T. M. (2009) · AIDS · doi:10.1097/qad.0b013e32832fef5b · Cited by 43
Moyle, G. J., Boffito, M., Stoehr, A. D., Rieger, A., Shen, Z., Manhard, K. J., Sheedy, B., Hingorani, V. N., Raney, A. K., Nguyễn, M. Á., et al. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00268-10 · Cited by 42
Kinetics and Mechanism of Hydrolysis of Efavirenz
Maurin, M. B., Rowe, S. M., Blom, K. F., et al. (2002) · Pharmaceutical Research · doi:10.1023/a:1015160132290 · Cited by 40
Next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors.
Boone, L. R. (2006) · PubMed · Cited by 33
Kakuda, T. N., Sekar, V. J., Vis, P., Coate, B., Ryan, R. J., Anderson, D., Rosa, G. D. L., & Mrus, J. M. (2012) · AIDS Research and Treatment · doi:10.1155/2012/186987 · Cited by 30
Calanolides, the naturally occurring anti-HIV agents.
Xu, Z., Flavin, M. T., & Jenta, T. R. ‐. (2000) · PubMed · Cited by 20
Características de los fármacos antirretrovirales
Ribera, E., Tuset, M., Martín, M., & del Cacho, E. (2011) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2011.02.004 · Cited by 16
Zala, C., Clair, M. S., Dudas, K. C., Kim, J. D., Lou, Y., White, S., Piscitelli, S., Dumont, E., Pietropaolo, K., Zhou, X., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05597-11 · Cited by 16
Hodder, S., Jayaweera, D. T., Mrus, J. M., Ryan, R. J., & Witek, O. B. O. T. G. S. J. (2011) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2011.0118 · Cited by 13
Simplification of antiretroviral therapy with etravirine.
Martínez, E., & Nelson, M. R. (2010) · PubMed · Cited by 9
Huang, F., Allen, L., Huang, D. B., Moy, F. S., Vinisko, R., Nguyen, T., Rowland, L., MacGregor, T. R., Castles, M. A., & Robinson, P. A. (2010) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2010.01235.x · Cited by 5
Cited by
Impact of HIV‐related stigma on treatment adherence: systematic review and meta‐synthesis
Katz, I. T., Ryu, A. E., Onuegbu, A. G., Psaros, C., Weiser, S. D., Bangsberg, D. R., & Tsai, A. C. (2013) · Journal of the International AIDS Society · doi:10.7448/ias.16.3.18640 · Cited by 1,126
Scott, K., Beckham, S. W., Gross, M., Pariyo, G., Rao, K. D., Cometto, G., & Perry, H. B. (2018) · Human Resources for Health · doi:10.1186/s12960-018-0304-x · Cited by 732
Dang, B. N., Westbrook, R. A., Njue, S. M., & Giordano, T. P. (2017) · BMC Medical Education · doi:10.1186/s12909-017-0868-5 · Cited by 278
Avoiding drug resistance in HIV reverse transcriptase
Cilento, M. E., Kirby, K. A., & Sarafianos, S. G. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00967 · Cited by 106
From 'real rape' to real justice: A systematic review of police officers' rape myth beliefs
Parratt, K. A., & Pina, A. (2017) · Aggression and Violent Behavior · doi:10.1016/j.avb.2017.03.005 · Cited by 100
Metadata
- Authors
- Usach, I., Melis, V., & Peris, J.
- Venue
- Journal of the International AIDS Society
- Publisher
- Wiley
- Published
- 2013-01
- Volume
- 16
- Issue
- 1
- Pages
- 1-14
- ISSN
- 1758-2652 (ISSN-L)
- OpenAlex
- W1994500331
- Cited by
- 373
- References
- 65
- FWCI
- 22.89
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.